Previous in vivo studies have established that pituitary nitric oxide synthase type 1 (NOS1) is regulated by gonadotropinreleasing hormone (GnRH). The aim of our study was to elucidate the mechanisms of NOS1 regulation by GnRH in rat pituitary cells. Using a perifused cell system, we demonstrated that NOS1 induction was sensitive to GnRH pulse frequency and was maximally induced under continuous GnRH stimulation. In primary cultures of rat pituitary cells, sustained stimulation with the GnRH agonist triptorelin (GnRHa) increased NOS1 protein levels, whereas NOS2 and NOS3 levels were unaffected. NOS1 up-regulation occurred in gonadotroph cells only, in a timedependent and concentration-dependent manner (maximum increase, 2.5-fold; half-maximal concentration, 0.17 nM). GnRHa effect was mimicked by cAMP pathway activators and, most importantly, was blocked by disruption of the protein kinase A (PKA) pathway using pharmacological inhibitors such as Rp-cAMP or drug phosphatase technology-protein kinase inhibitor (DPT-PKI), a cell-permeant PKI peptide. In contrast, modulation of the PKC pathway and inhibition of the MAPK cascade were ineffective. Overall, these experiments demonstrated that GnRH-induced up-regulation of pituitary NOS1 is mediated notably by the cAMP/PKA pathway. Last, in vivo administration of a GnRH antagonist markedly inhibited the pituitary cAMP rise at proestrus in addition to suppressing NOS1 increase. Altogether, our data suggest that the cAMP/PKA signaling pathway is preferentially recruited under sustained GnRH stimulation in vivo during proestrus, allowing the expression of a specific set of PKA-regulated proteins, including NOS1, in gonadotroph cells.
INTRODUCTION
The hypothalamic neuropeptide gonadotropin-releasing hormone (GnRH) is the major regulator of the reproductive system of mammals. GnRH is released in a pulsatile manner by hypothalamic neurons and reaches the anterior pituitary via the hypophysial portal circulation, where it controls both the biosynthesis and release of the two gonadotropin hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1] . In addition to the three gonadotropin subunit genes (Cga, Lhb, and Fshb), GnRH is now known to regulate the expression of numerous other genes in gonadotroph cells. Results from both in vivo and in vitro studies have established that the pattern of GnRH pulse frequency regulates differentially the expression of many genes, including notably those encoding gonadotropin subunits [2] . Indeed, low frequencies preferentially induce Fshb transcription, whereas higher frequencies preferentially stimulate Lhb and Cga genes. Furthermore, transcription of Cga gene is maintained under permanent in vivo exposure to GnRH, contrasting with the rapid depletion of both b subunit transcripts. The intracellular signaling mechanisms that decode GnRH pulse frequency information still remain to be understood.
GnRH acts through a heptahelical receptor of the G proteincoupled receptor (GPCR) family, the mammalian type I GnRH receptor (GnRH-R), which is specifically expressed in gonadotroph cell membranes. This receptor is characterized by the unique absence among GPCRs of a C-terminal tail, which is the target for homologous and heterologous phosphorylation. As a result, GnRH-R is resistant to rapid desensitization and only displays a low level of constitutive agonist-independent internalization [3, 4] . Upon ligand binding, GnRH-R activates a variety of downstream signaling pathways through the initial recruitment of phospholipase Cb via Gaq/11. This leads to a rapid increase in intracellular Ca 2þ level and stimulation of several protein kinase C (PKC) isoforms, which activate a complex signaling network accounting for most of the biological effects of GnRH [5] . In addition to triggering gonadotropin release, elevation of intracellular Ca 2þ also activates the nitric oxide synthase type 1 (NOS1) cascade (NOS1/NO/soluble guanylate cyclase [sGC] ), resulting in a rapid increase in cGMP. GnRH-recruited PKC activates proteins of the MAPK cascade, which are notably involved in the regulation of gonadotropin subunit gene transcription. Contrasting with all those well-character-ized pathways, the contribution of the cAMP/PKA signaling pathway in GnRH action remains elusive, although cAMP is known to be crucial for the regulation of gonadotroph function. Indeed, it has been clearly demonstrated that cAMP contributes to the regulation of several genes, including gonadotropin subunits or Gnrhr in gonadotrophs and also enhances the release of newly synthesized LH [6] [7] [8] . Paradoxically, the ability of GnRH to induce cAMP accumulation in gonadotroph cells and the mechanisms linking GnRH-R to adenyl cyclase activation have long remained controversial, thus calling into question the precise contribution of this pathway to GnRH action. However, there is now clear evidence that GnRH increases cAMP production in the differentiated gonadotroph cell line LbT2 [9, 10] . Intriguingly, GnRH coupling to the cAMP pathway seems to take place in response to sustained receptor activation only [10] , suggesting that this pathway may be selectively induced under high-frequency GnRH secretion as observed, for example, during the preovulatory period. Supporting this idea, pituitary cAMP levels in female rats have been reported to significantly increase in vivo during the proestrous afternoon, although the precise contribution of GnRH in such cAMP production has never been elucidated [11] .
The renewed interest for cAMP signaling in gonadotrophs has led to the recent identification of a small number of genes regulated by GnRH through the cAMP/PKA signaling pathway. These include Fst [12, 13] , Nr4a1 [14] , and Adcyap1 [15] genes. Several lines of evidence, obtained mainly from our laboratory, suggest that the neuronal NOS (Nos1) gene may be a potential additional candidate. NOS1 belongs to the NOS enzyme family comprising three major isoforms, NOS1 (neuronal NOS), NOS2 (inducible NOS), and NOS3 (endothelial NOS), which all catalyze the formation of NO, a key signaling molecule involved in numerous physiological and pathological processes [16] . Most of the effects of NO are mediated through cGMP formation. NOS1 isoform expression is not restricted to the central and peripheral nervous system, as NOS1 is expressed in several nonneuronal tissues, including the pituitary. In the anterior pituitary gland, NOS1 is specifically detected in gonadotroph and folliculostellate cells [17, 18] . In vivo experiments have clearly established that GnRH is a key regulator of NOS1 in pituitary gonadotrophs. An interesting feature of such a regulation is that NOS1 appeared to be preferentially induced in vivo under sustained stimulation, as maximum NOS1 induction was obtained only after 24-h treatment of rats with GnRH [18] . Accordingly, NOS1 expression was reported to be selectively up-regulated in pituitary gonadotrophs during the preovulatory GnRH surge [19] . All these data suggested that GnRH may regulate pituitary NOS1 through the cAMP pathway, but such mediation remains to be demonstrated. Moreover, if both cAMP recruitment and NOS1 induction in gonadotrophs are preferentially induced during sustained GnRH stimulation, this would suggest that they are functionally linked in vivo during specific physiological stages such as the preovulatory GnRH surge.
The present experiments were conducted to test these hypotheses. First, using a perifused pituitary cell system, we analyzed whether NOS1 induction was sensitive to GnRH pulse frequency. Second, in addition to classical pharmacological agents, we took advantage of drug phosphatase technology-protein kinase inhibitor (DPT-PKI), a specific cell-permeant PKA inhibitor peptide to evaluate the contribution of the cAMP/PKA signaling pathway in GnRH regulation of NOS1 in primary cultures of rat anterior pituitary cells. Third, because the proestrous stage of the ovarian cycle is characterized by a sustained GnRH secretion, we studied in vivo the effects of a GnRH antagonist treatment on pituitary cAMP and NOS1 levels during the preovulatory period. 
MATERIALS AND METHODS

Materials
Animals and Treatments
All studies were conducted in accord with the National Research Council (Washington, DC) publication Guide for the Care and Use of Laboratory Animals (1996, National Academy Press) and with approval from the experimental animal committee of the Jacques Monod Institute, Paris, France. Adult Wistar rats (200-250 g, René Janvier, St. Isle, France) were housed in a temperature-controlled room with 12L:12D and free access to tap water and standard laboratory chow. For the in vivo treatment of female rats with GnRH antagonist, estrous cyclicity was monitored by daily examination of vaginal smears, and only animals exhibiting at least two consecutive 4-day estrous cycles were used in the experiments. Rats were killed by decapitation at 2000 h during either diestrus II or proestrus. Some rats were subcutaneously injected with the potent antagonist ganirelix (a single injection of 100 lg) or its vehicle at 2000 h on diestrus II and killed 24 h later. Anterior pituitaries were rapidly excised and cut into halves for either Western blotting of NOS1 or cAMP assay. Trunk blood was collected for determination of LH level.
Perifusion Experiments
Anterior pituitary glands were removed from male Wistar rats, and cells obtained after enzymatic dissociation were suspended in Dulbecco modified Eagle medium (DMEM) supplemented with 15 mM Hepes/15 mM NTris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES), 1 g/L of NaHC0 3 , 2% Ultroser SF (USB; IBF France, L'Horme, France), and 0.1% antibiotics. They were maintained under constant gyratory shaking to allow the formation of aggregates of pituitary cells [20] . On Day 7, aggregates (8-10 3 10 6 cells) were loaded into temperature-controlled (378C) chambers of a computer-driven perifusion system. The perifusion medium (serum-free DMEM supplemented with 0.03% bovine serum albumin constantly gassed with 5% CO 2 ) was pumped through the chambers at a flow rate of 200 ll/min. After an initial 5-h stabilization period, cells in parallel chambers were treated or not for 24 h with 10 nM GnRH at two different pulse frequencies (1-min pulse every 30 min and 1-min pulse every hour) or continuously. Effluent fractions were collected every 20 min over the 24-h treatment for determination of LH concentrations. Aggregates were recovered at the end of each experiment and immediately deep frozen in liquid nitrogen for analysis of NOS1 content.
Primary Culture of Anterior Pituitary Cells
Anterior pituitary glands underwent a trypsin dissociation procedure as previously described [8] . Dispersed cells were plated at a density of 2 3 10 6 cells in 12-well plates in Ham F-10 medium containing 10% fetal calf serum and antibiotics (100 U/ml of penicillin and 100 lg/ml of streptomycin) and incubated for 3 days at 378C in a humidified atmosphere with 5% CO 2 . After an overnight incubation in serum-free Ham F-10, cells were treated for 24 h with GnRHa, 8-Br-cAMP, cholera toxin, A23187, or PMA. Cells were also pretreated with IBMX, BIM, PD98059, H89, Rp-cAMP, ethyleneglycoltetracetic acid (EGTA), L-NMMA, or ODQ for 30 min before stimulation with GnRHa. After stimulation, the medium was collected and stored at À208C for determination of LH release. Cells were then washed with cold PBS before protein extraction. All experiments were performed in triplicate.
NADPH Diaphorase Cytochemistry
Dispersed pituitary cells (0.5 3 10 6 cells) were plated in poly-L-lysinecoated chambers of Lab-Tek slides (Nunc, VWR, Strasbourg, France) in Ham F-10 medium. After 3 days, the medium was replaced, and the cells were incubated or not with 1 nM triptorelin for 24 h. Cells were then fixed in 4% GnRH INDUCES PITUITARY NOS1 VIA THE PKA PATHWAY paraformaldehyde for 20 min and rinsed three times for 10 min with PBS before permeabilization by incubation with 0.1% saponin for 15 min. After several washes with PBS, the NADPH diaphorase cytochemical procedure was performed as described previously [18] . Briefly, cells were incubated in the dark at 378C for 30 min in 50 mM Tris-HCl (pH 8) containing 1 mg/ml of b-NADPH, 0.1 mg/ml of nitroblue tetrazolium salt, and 0.3% Triton X-100. Gonadotroph cells were then identified by immunocytochemistry using a mouse monoclonal anti-bovine LHb antibody as previously described [21] , which was revealed using the Alexa Fluor 568 secondary antibody (1:1000 dilution; Invitrogen, San Diego, CA). The slides were finally mounted with Citifluor AF-1 (Biovalley, Marne-la-Vallée, France) and observed under an epifluorescence microscope (90i; Nikon, Champigny-sur-Marne, France).
Use of DPT-PKI to Specifically Inhibit PKA in Dispersed Pituitary Cells
We have recently characterized a new specific cell-permeable PKA inhibitor named DPT-PKI. It contains a bipartite sequence that results from the fusion of 12 amino acids of our published DPT-sh1 shuttle [22] with 20 amino acids of the nonpenetrating peptide PKI 5-24 that specifically inhibits PKA. DPT-PKI was used for specific PKA inhibition of cultured pituitary cells. Biotinylated DPT-sh1-penetrating and DPT-PKI-penetrating peptides were synthesized as described [22, 23] and were reconstituted in 150 mM NaCl. Peptides were added at 100 lM to pituitary cells for 8 h at 378C before stimulation with GnRHa (1 nM) for an additional 16-h period. Cells were then washed with cold PBS, and proteins were extracted and processed for immunodetection of NOS1. Successful intracellular delivery was assessed by fluorescence microscopy. Dispersed pituitary cells (0.5 3 10 6 cells) were plated in poly-L-lysine-coated chambers of Lab-Tek slides in Ham F-10 medium. After 24-h treatment with biotinylated DPT-sh1 or DPT-PKI, cells were fixed in 4% paraformaldehyde for 20 min. After several washes with PBS, cells were permeabilized in PBS containing pig gelatin (2 g/L) and 0.1% Triton X-100 for 30 min. Cells were then incubated for 1 h at room temperature with streptavidin-fluorescein complex (1:100 dilution) for biotinylated peptide detection. Cells were counterstained with the chromatin dye Hoechst and then mounted in AF1 Citifluor medium (Biovalley) before visualization by fluorescence microscopy.
Protein Extraction and Immunoblotting
Pituitary cells were washed with cold PBS and homogenized in a buffer containing 10 mM Tris-HCl (pH 7.4), 2 mM EGTA, and 1% Triton X-100 supplemented with a protease and phosphatase inhibitor cocktail (Roche, Welwyn Garden City, U.K.). Homogenates were centrifuged at 20 000 3 g for 30 min at 48C, and protein concentration was determined using the Bio-Rad (Hercules, CA) protein assay. Protein extracts (35 lg) were separated using 7% SDS-PAGE. After electrotransfer onto nitrocellulose membrane, NOS1, NOS2, and NOS3 were immunodetected using specific antibodies (1:200, 1:1000, and 1:500 dilutions, respectively). Blots were developed using horseradish peroxidase-conjugated secondary antibodies and ECLþ reagent (GE Healthcare, Waukesha, WI), analyzed with a Fuji LAS-4000 imager (FujiFilm, Tokyo, Japan), and quantified using Multi Gauge software analysis (FujiFilm). Blots were stripped and reprobed with an antibody against b-actin (1:4000 dilution; Sigma). b-Actin values were used as an internal loading control in order to normalize NOS1 expression.
Nos1 RNA Analysis by Real-Time RT-PCR
Total RNA from rat anterior pituitary cells was isolated with an RNeasy-kit (Qiagen, Studio City, CA), and cDNA was obtained with Superscript II RT (Invitrogen) according to the manufacturer's instructions. Real-time PCR analyses were carried out using Light Cycler 480 SYBR Green I Master mix (Roche). Relative quantification of gene expression was performed using Hprt as an internal control. Rat-specific Nos1 primers were 5 0 -TGCAGGAGGA GAGAAAGAGC-3 0 (sense) and 5 0 -CCAGGGGTCCAGTACTTTCA-3 0 (antisense). Cycling conditions were as follows: 958C for 10 min, followed by 40 cycles of 958C for 10 sec, 608C for 10 sec, and 728C for 10 sec. After PCR, the product was identified as a single band of the appropriate size on ethidium bromide gel. Each sample was analyzed in duplicate. The threshold cycle and the standard curve method were used for calculating the relative amount of the target RNA.
Gonadotropins and cAMP Assays
Gonadotropin (LH and/or FSH) concentrations were determined in the culture media of perifused and static cultures of pituitary cells, as well as in rat sera. Blood samples were centrifuged at 1000 3 g for 20 min at 48C, and sera were stored at À208C until use. For cAMP determination, hemipituitaries were quickly frozen after dissection and kept in liquid nitrogen until use. Hemipituitaries were then homogenized in 5% trichloroacetic acid before cAMP level determination. The LH and FSH concentrations were determined using commercial radioimmunoassay and ELISA kits, respectively (Immunodiagnostic Systems, Paris, France). The cAMP concentrations were determined with a competitive enzyme immunoassay kit (Cayman Chemical Company, Ann Arbor, MI). Assay sensitivities were 0.14 ng/ml, 0.2 ng/ml, and 0.1 pmol/ ml, and interassay coefficients of variation were 12.2%, 8.5%, and 4.1% for LH, FSH, and cAMP, respectively.
Statistical Analysis
All given values are the mean 6 SEM of at least three independent experiments with three replicates for each experimental group. Statistical differences were first determined by one-way ANOVA, followed by Dunnett ttest for multiple comparisons. Individual pairwise comparisons were performed using Student t-test. P 0.05 was considered significant.
RESULTS
NOS1 Expression Is Only Induced Under Sustained GnRH Stimulation in Perifused Rat Pituitary Cells
In order to explore whether NOS1 expression was sensitive to the frequency of GnRH pulsatile stimulation, we used a perifusion system that allowed the application of an intermittent GnRH pulsatile signal to rat anterior pituitary cells. As shown in Figure 1 , cells were exposed for 24 h to 10 nM native GnRH delivered either at one or two 1-min pulses per hour or continuously, reflecting the varying in vivo secretion of the neuropeptide [24, 25] . Hourly pulses of GnRH did not induce any change of NOS1 level, whereas a higher frequency (two pulses per hour) significantly increased NOS1 expression. Maximal induction was reached under conditions of continuous GnRH stimulation. To assess the efficacy of each GnRH pulse regimen, LH concentrations were determined in effluent fractions collected every 20 min of the 24-h treatment. As shown in Figure 1B , all GnRH treatments induced a significant LH response. However (and as expected from the literature [1, 3] ), whereas pulsatile GnRH administration led to a pulsatile pattern of LH release, continuous GnRH treatment induced a massive LH release, followed by a loss of pituitary cell response to further GnRH stimulation. Altogether, these data show that NOS1 induction in pituitary cells is sensitive to GnRH pulse frequency and is maximally induced under continuous GnRH secretion.
GnRH Stimulates NOS1 Expression in a Time-Dependent and Concentration-Dependent Manner in Primary Cultures of Rat Pituitary Cells
To analyze the mechanisms involved in GnRH regulation of NOS1 expression, we first performed time course ( Fig. 2A) and concentration-dependent (Fig. 2B ) experiments on primary cultures of anterior pituitary cells. Pituitary cells were incubated for increasing periods (2-48 h) with 1 nM triptorelin (GnRHa), and NOS1 protein level was determined by immunoblotting. NOS1 level significantly increased at 8 h, with an expression of 155% 6 6% over basal level. Maximal induction was reached at 24 h (230% 6 9% over basal level), and NOS1 levels remained elevated until 48 h (Fig. 2A) . No significant levels of immunoreactive NOS2 nor NOS3 could be detected in unstimulated pituitary cells, and GnRHa did not affect the levels of these two NOS isoforms (data not shown). An increase in NOS1 protein level was preceded by a significant increase in Nos1 transcript level at 4 h after GnRHa stimulation, as revealed by quantitative RT-PCR analysis ( Fig. 2A, inset) . Nos1 mRNA levels remained significantly increased at 24 h (2 6 0.05-fold 1172 over basal level). To further analyze the action of GnRH, pituitary cells were then stimulated for 24 h with various concentrations (0.05-5 nM) of GnRHa (Fig. 2B) . Increasing GnRHa concentrations resulted in a significant dose-dependent increase of NOS1 protein levels. The maximal response was reached at 1 nM GnRHa (2.5-fold), with a deduced halfmaximal concentration of 0.17 nM. Treatment of cells with 5 lM of the GnRH antagonist antarelix completely blocked the effect of 1 nM GnRHa, demonstrating that this effect was specifically induced by activation of GnRH-R. A similar increase in NOS1 levels was induced by stimulation of pituitary cells with the native GnRH (2.8-fold increase over basal level after a 24-h stimulation with 10 nM GnRH [data not shown]). We next localized NOS1 using NADPH diaphorase cytochemistry to identify the type of endocrine cells exhibiting such an increase in NOS1 expression. As shown in Figure 2C , GnRHainduced increase of NOS1 expression occurred in gonadotroph cells as evidenced by coimmunodetection of LHb. Immunodetection of endocrine cells and folliculostellate cells further established that GnRHa-induced NADPH diaphorase activity was restricted to gonadotroph cells only (data not shown).
GnRH Activation of NOS1 Expression in Gonadotroph Cells Is Mediated Through the cAMP Pathway
To determine the signaling pathways involved in GnRH effects on NOS1 protein expression, we first treated pituitary cells with several pharmacological agents. As shown in Figure  3A , increasing intracellular cAMP level by stimulation of cells with a potent activator of stimulatory G protein alpha subunit (Gas) (3 nM cholera toxin) and by incubation with a cellpermeable cAMP analog (1 mM 8-Br-cAMP) significantly increased NOS1 expression (4.0-fold and 3.9-fold over basal levels, respectively). Treatment of cells with the phosphodiesterase inhibitor IBMX significantly potentiated GnRHa effect on NOS1 level (2.7-fold and 3.7-fold over basal level for GnRHa and GnRHa plus IBMX, respectively), further supporting cAMP involvement. In contrast, neither the phorbol ester PMA (5 nM), known to directly activate most PKC, nor the Ca 2þ ionophore A23187 (5 lM), leading to elevation of cytosolic Ca 2þ , affected NOS1 level. Another Ca 2þ ionophore, ionomycin, and the L-type calcium channel agonist BayK 8644 were also tested and did not influence NOS1 expression (data not shown). The ability of each drug to induce LH release in anterior pituitary cells was evaluated. This showed that, although PMA and A23187 failed to stimulate NOS1 expression, both drugs triggered LH release with the same efficacy as 8-Br-cAMP or cholera toxin (1199% 6 119%, 919% 6 149%, 950% 6 100%, and 810% 6 10.6% over basal LH release for PMA, A23187, 8-Br-cAMP, and cholera toxin, respectively) (data not shown).
In agreement with these results, pretreatment of anterior pituitary cells with the PKA inhibitor H89 (10 lM) or RpcAMP (1 mM) markedly inhibited GnRHa-induced increase in FIG. 1. A) NOS1 up-regulation requires high-frequency or continuous stimulation by GnRH in perifused rat anterior pituitary cells. Anterior pituitary cells were submitted for 24 h to different GnRH pulse frequencies in a perifusion system. Cells were stimulated by 10 nM native GnRH either continuously or under one or two 1-min pulses per hour. NOS1 level was analyzed by immunoblotting as indicated in Materials and Methods, and a representative blot is shown for each condition. b-actin was used as a loading control. Data are expressed as percentage over the respective basal level and are the mean 6 SEM of three independent experiments. **P 0.01 compared with basal level. B) Profiles of LH release as a control for GnRH treatment efficiency. Effluent fractions were collected every 20 min over the 24-h treatment for LH radioimmunoassay as indicated in Materials and Methods. The panels show a representative experiment for each condition of stimulation. The arrow indicates the beginning of GnRH treatment.
GnRH INDUCES PITUITARY NOS1 VIA THE PKA PATHWAY NOS1 expression (63% 6 7% and 55% 6 3% inhibition for H89 and Rp-cAMP, respectively) (Fig. 3B) . The effect of GnRHa was also significantly reduced when cells were incubated in a Ca 2þ -free medium (2.5 mM EGTA). In contrast, inhibition of PKC with the pharmacological inhibitor BIM (2 lM) did not prevent GnRH-induced NOS1 expression, although it significantly blocked the effect of GnRH on LH release (40% 6 5% inhibition) (data not shown), thus suggesting that the PKC pathway is not involved. Similarly, the MAPK inhibitor PD98059 (20 lM) did not inhibit GnRHa effect (Fig. 3B) .
To further assess the involvement of the cAMP pathway in GnRH activation of NOS1 expression, we disrupted this pathway by introducing the potent endogenous PKA inhibitor PKI in pituitary cells. For this purpose, cells were treated with the DPT-PKI-permeant peptide, which was biotinylated in order to evaluate its internalization and cellular localization. Figure 4A shows that DPT-PKI penetrated most pituitary cells and localized to the cytoplasm as previously observed in other cell types [23] . The shuttle DPT-sh1 displayed similar internalization and cellular localization (data not shown). As shown in Figure 4B , stimulation of cells for 16 h with GnRHa significantly increased NOS1 expression by 1.75 6 0.05-fold and 1.84 6 0.1-fold over basal level in control and shuttletreated cells, respectively, and only by 1.40 6 0.05-fold in DPT-PKI-treated cells. Treatment with DPT-PKI thus significantly reduced GnRHa effect. DPT-PKI also slightly decreased basal NOS1 expression in pituitary cells. Furthermore, DPT-PKI significantly reduced GnRHa-induced LH release (48% 6 13% inhibition) (data not shown) in agreement with the known role of cAMP in the release of newly synthesized LH [8] . Altogether, these results demonstrate a major contribution of the cAMP/PKA pathway in the GnRH regulation of NOS1 expression in pituitary gonadotroph cells.
We next evaluated whether inhibition of NOS or sGC activities may alter GnRH-induced release of LH and FSH in cultured pituitary cells. Inhibition of NOS and sGC using 1 mM L-NMMA and 1 lM ODQ, respectively, did not interfere with the cell secretory response to GnRHa, which was evaluated at three different times (Table 1) . Furthermore, no significant gonadotropin release could be induced by stimulation of cells with 1 mM 8-Br-cGMP or 0.1 mM sodium nitroprusside, an NO donor (data not shown).
Proestrous Rise of cAMP Is Prevented In Vivo by GnRH Antagonist
Anterior pituitary cAMP levels have been long reported to fluctuate during the estrous cycle of rats, exhibiting a significant increase in the afternoon of proestrus [11] . Although such increase coincided with the preovulatory GnRH surge, the exact contribution of GnRH has not been evaluated. We thus administered the potent GnRH antagonist ganirelix to female rats at 2000 h on the day of diestrus II and measured pituitary cAMP concentrations 24 h later on proestrous day. Serum LH levels were used as the reference. As expected, serum LH concentration increased significantly at 2000 h on proestrous day, and treatment with the GnRH antagonist suppressed the LH surge, demonstrating the efficacy of the antagonist treatment (Fig. 5) . Pituitary cAMP concentrations displayed a substantial increase at 2000 h on proestrous day compared with diestrus II (2.3 6 0.3-fold) . Treatment with the GnRH   FIG. 4 . Inhibition of GnRH effect on NOS1 expression by the specific cell-permeant PKA inhibitor DPT-PKI. A) Intracellular localization of DPT-PKI in primary culture of rat anterior pituitary cells. Cells were incubated for 24 h with 100 lM biotinylated DPT-PKI, and peptide cellular penetration was determined by fluorescence microscopy analysis and achieved using streptavidin-fluorescein complex as indicated in Materials and Methods. Nuclei were visualized by DNA staining with the fluorescent dye Hoechst 33258. B) Effects of DPT-PKI on GnRH-induced increase of NOS1 level. Anterior pituitary cells were incubated or not (control) for 8 h with 100 lM DPT-PKI or the control shuttle DPT-sh1 before addition of 1 nM GnRHa for the next 16 h. NOS1 level was then determined, and a representative blot is shown for each condition. Data are expressed as percentage over unstimulated control cells and are the mean 6 SEM of three independent experiments. *P 0.05 and **P 0.01 compared with control unstimulated cells.
FIG. 3.
The cAMP/PKA pathway mediates GnRH stimulation of NOS1 expression. A) GnRH effect on NOS1 expression is mimicked by pharmacological activators of the cAMP pathway. Anterior pituitary cells were treated for 24 h with 1 nM GnRHa alone or in combination with 2.5 mM IBMX. They were otherwise stimulated with 1 mM 8-Br-cAMP, 3 nM cholera toxin, 5 lM A23187, or 5 nM PMA. Cell protein extracts were analyzed by Western blotting, and NOS1 level was determined as in Figure 1 . All values are expressed relative to unstimulated cells (basal) and are the mean 6 SEM of three to five independent experiments. **P 0.01 compared with basal level. B) PKA inhibitors partially block GnRH effect on NOS1 expression. Anterior pituitary cells were stimulated for 24 h with 1 nM GnRHa alone or in combination with 10 lM H89, 1 mM Rp-cAMP, 2.5 mM EGTA, 2 lM BIM, or 20 lM PD98059. NOS1 level was determined as in Figure 1 . None of these drugs significantly affected basal NOS1 level (86% 6 6%, 95% 6 5%, 91% 6 9%, 95% 6 65%, and 96% 6 12% of basal NOS1 level for H89, Rp-cAMP, EGTA, BIM, and PD98059, respectively). Data are expressed as the percentage of maximal NOS1 induction by GnRHa and are the mean 6 SEM of three independent experiments. **P 0.01 compared with GnRHa-stimulated cells (100%).
antagonist markedly suppressed the cAMP elevation (75% 6 4% inhibition), demonstrating a major contribution of GnRH to the proestrus-specific cAMP rise in rat pituitary (Fig. 5) . Administration of vehicle alone did not affect cAMP concentrations (2.1 6 0.2-fold increase over diestrus II) (data not shown). Moreover, proestrus-specific elevation of pituitary NOS1 level was also significantly suppressed after administration of ganirelix as previously reported using another GnRH antagonist [19] . Altogether, these data establish a physiological link in vivo between GnRH, cAMP production, and NOS1 induction during the estrous cycle.
DISCUSSION
Although NOS1 has been reported to be primarily regulated by GnRH [18, 19] , the signaling pathways involved in such regulation have not been firmly elucidated in pituitary gonadotrophs. Because it is now recognized that GnRH can couple to cAMP signaling in the gonadotroph cell line LbT2, we evaluated the contribution of this pathway to GnRH regulation of NOS1 expression in pituitary gonadotrophs. Using primary cultures of rat anterior pituitary cells, we clearly established that stimulation with GnRH specifically upregulates pituitary NOS1 expression in a time-dependent and concentration-dependent manner. In contrast, there was no detectable expression of NOS2 or NOS3 in anterior pituitary cells as previously reported [18, 21] , and their expression was unaffected by GnRH. Moreover, GnRH induced NOS1 only in gonadotroph cells as evidenced by NADPH diaphorase cytochemistry and in agreement with our previous results obtained in vivo after treatment of rats with GnRH [18, 19] . We can assume from these previous in vivo studies that GnRH regulates NOS1 specifically in gonadotrophs, and the suppressive effect of the GnRH antagonist observed in the present study is consistent with such a hypothesis. Herein, we report that GnRH increased Nos1 mRNA level in pituitary cell cultures in agreement with its reported stimulatory effect on Nos1 gene promoter activity [26] . The involvement of the cAMP pathway was demonstrated by several complementary experimental strategies. We first showed that 8-Br-cAMP or drugs increasing intracellular cAMP level (such as IBMX or cholera toxin) mimicked the effect of GnRH on NOS1 expression, whereas the pharmacological PKA inhibitor H89 markedly inhibited it. To further confirm the results obtained with H89, reportedly interfering with non-PKA targets [27] , we provided evidence that another pharmacological PKA inhibitor, Rp-cAMP, also inhibited the GnRH effect. Moreover, GnRH action was also decreased after PKA activity disruption using the potent natural PKI. This was done by taking advantage of the DPT-PKI peptide strategy, which allowed an efficient delivery of the PKI [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] peptide in primary cultures of pituitary cells. Altogether, these studies demonstrate the involvement of the cAMP/PKA pathway in the regulation of pituitary NOS1 by GnRH. Our study thus identifies Nos1 as an additional gene among the very few genes regulated by GnRH through the cAMP pathway 1176 identified so far. Because GnRH is also coupled to the PKC pathway in gonadotroph cells, we evaluated the role of this signaling pathway in regulating NOS1 level. Treatment of cells with PMA, a potent activator of PKC, did not increase NOS1 level. In addition, the pharmacological PKC inhibitor BIM did not interfere with GnRH, suggesting that the PKC signaling pathway is not involved in the NOS1 induction by GnRH. In fact, pharmacological inhibition of the MAPK cascade, known to be mainly activated by PKC in gonadotroph cells, was also ineffective. Such data contrast with our recent study [10] of LbT2 cells demonstrating that, in addition to the previously reported coupling via Gas [9] , GnRH induction of cAMP also depends on recruitment of novel PKC isoforms. Differences between the two gonadotroph cell lines aT3-1 and LbT2 have also been reported, as GnRH does not activate the cAMP pathway in the aT3-1 gonadotroph cell line, in which neither PKC nor Gas seems to be functionally coupled to such a pathway. Altogether, these results suggest that the mechanisms linking GnRH-R activation and cAMP production may differ between pituitary gonadotroph cells and clonal cell lines. The role of calcium in the regulation of NOS1 expression was also addressed. Pharmacological depletion of intracellular and extracellular calcium by incubation of cells with EGTA reduced the effect of GnRH. However, triggering Ca 2þ influx by treatment of cells with either ionophores (such as A23187 or ionomycin) or an L-type calcium channel agonist failed to increase NOS1 expression. Taken together, this suggests that intracellular calcium but not calcium influx is necessary but not sufficient to mediate GnRH effect on NOS1 expression. The present demonstration of cAMP/PKA involvement, together with the previously reported role of cAMP response element-binding (CREB) protein in the regulation of the Nos1 gene by GnRH [28] , suggests that CREB may contribute to GnRH regulation of pituitary Nos1. In support of such a hypothesis, CREB was reported to be phosphorylated by GnRH in rat pituitary [29] . This, however, does not exclude the contribution of other transcription factors.
It has long been established that the frequency of GnRH pulses determines the ratios of the gonadotropin subunit expression, and this has been proposed as one of the mechanisms allowing gonadotroph cells to interpret the varying pattern of GnRH secretion [25] . Gonadotropin genes are, however, far from being the only genes affected by GnRH, and recent microarray studies [30, 31] performed on gonadotroph cell lines have revealed that a large panel of genes is differentially regulated by GnRH pulse frequency. Our present study using pituitary cells in a perifusion system indicates that Nos1 is one of these genes. Indeed, NOS1 was not induced by GnRH delivered at a frequency of one pulse per hour, although this frequency was able to trigger a sustained LH release all along the stimulation. In contrast, NOS1 was maximally induced by continuous GnRH stimulation, contrasting with LH release, which underwent desensitization in response to such treatment. This observation is in agreement with our previous in vivo data showing that NOS1 induction remained at high levels for at least 48 h under long-lasting GnRHa treatment, contrasting with the concomitant inactivation of gonadotropin release [18] . This is also reminiscent of the reported regulation of follistatin expression [32, 33] . Nos1 thus appeared to be one of the few genes, including the prototypic Cga, exhibiting resistance to the inhibitory effects of permanent GnRH stimulation. The Cga mRNA level has been reported to remain constant for days in rats under sustained GnRH, whereas both b subunit transcripts were significantly altered [34] . This is consistent with the reported increase of free a subunit levels in long-term GnRH-treated patients [35] . Our present observation that NOS1 protein is still expressed and even enhanced under continuous GnRH stimulation is consistent with our previous in vivo data showing a maximum NOS1 expression at proestrus during the preovulatory GnRH surge [19] , characterized by a very high GnRH pulse frequency. Altogether, these data emphasize the unique feature of gonadotroph cells, which maintain part of their functional response under conditions of stimulation, inducing desensitization of most GPCRs. This is probably related to the atypical behavior of the mammalian GnRH-R, which (due to the lack of a C-terminal tail) exhibits resistance to rapid agonist-induced desensitization and internalization [3] .
Interestingly, the fact that GnRH-induced NOS1 increase is mediated by cAMP and is preferentially induced under sustained GnRH stimulation is consistent with our recent data demonstrating in LbT2 cells that GnRH only couples to the cAMP pathway under prolonged stimulation of GnRH-R [10] . This prompted us to evaluate the functional link between the GnRH preovulatory surge and the concomitant increase in pituitary cAMP levels reported in 1980 [11] . Indeed, the marked inhibitory effect of a GnRH antagonist provides evidence for a predominant role of GnRH in mediating the proestrus-specific cAMP rise. This was somewhat unexpected because other hypophysiotropic hypothalamic neuropeptides are known to be coupled to the cAMP pathway. One such neuropeptide is pituitary adenylate cyclase-activating polypeptide (PACAP), and we previously reported that NOS1 was also up-regulated by PACAP in pituitary cell cultures [21] . Assuming that these observations are pertinent to gonadotrophs in vivo, this would suggest that NOS1 is under the dual regulation of GnRH and PACAP, both acting through the cAMP pathway. As GnRH was recently reported to stimulate Adcyap1 gene expression [15] , notably via the cAMP pathway in LbT2 cells, we cannot exclude that PACAP may contribute, in an autocrine manner, to the observed GnRH effect on NOS1 expression. Because gonadotroph cells only account for 10%-15% of the total endocrine population of the pituitary, our data suggest that the cAMP pathway is maximally recruited by GnRH-R in gonadotrophs at proestrus. Hence, we can speculate that, under conditions of sustained GnRH stimulation, GnRH-R may preferentially activate the cAMP/ PKA pathway and initiate the expression of a new set of target proteins. For the first time to date, we have established that pituitary NOS1 belongs to this set of proteins. The fact that gonadotroph cells maintain their functional activity even under a desensitizing pattern of GnRH stimulation is probably one of the main mechanisms underlying their plasticity during the ovarian cycle. By providing evidence that the cAMP pathway is used to decode high GnRH input, our present work supports the idea that selective signaling may be a potential mechanism allowing gonadotroph cells to interpret GnRH pulse frequency.
The role of GnRH-dependent NOS1 induction at proestrus remains to be determined. Numerous in vivo and in vitro studies have established the contribution of the NOS system in the neuroendocrine control of reproduction. At the pituitary level, NOS1 impact on gonadotropin secretion still requires clarification. Our present work supports the idea that NO may not influence gonadotropin release as previously reported [36] [37] [38] . Indeed, pharmacological inhibition of NOS1 or sGC did not influence basal and GnRH-induced release of LH and FSH. However, the reported effects of NO are conflicting, with NO described either as inhibitory or stimulatory on gonadotroph cells [17, [39] [40] [41] . Several lines of evidence suggest that gonadotroph-originating NO may influence the secretory activity of other pituitary endocrine cells such as GnRH INDUCES PITUITARY NOS1 VIA THE PKA PATHWAY somatotropes, lactotropes, and corticotropes [42, 43] . Moreover, recent studies [44, 45] have highlighted the mediatory role of NOS1 in GnRH modulation of activin-induced or ghrelin-induced gonadotropin synthesis and/or release. Altogether, this suggests that NOS1 contributes to the coordinated regulation of pituitary function. The challenge is now to elucidate how the proestrus-specific GnRH mobilization of the NOS1 system in gonadotrophs contributes to pituitary functional adaptation at this crucial stage of the reproductive cycle.
